Development of encorafenib for BRAF-mutated advanced melanoma

PURPOSE OF REVIEW: To describe the pharmacological properties, preclinical and clinical data of the novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)-inhibitor encorafenib (LGX818) and to compare these with established BRAF-inhibitors in the treatment of locally advanced or metastatic melan...

Descripción completa

Detalles Bibliográficos
Autores principales: Koelblinger, Peter, Thuerigen, Olaf, Dummer, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
MELANOMA AND OTHER SKIN NEOPLASMS: Edited by Reinhard Dummer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815646/
https://www.ncbi.nlm.nih.gov/pubmed/29356698
http://dx.doi.org/10.1097/CCO.0000000000000426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815646/
https://www.ncbi.nlm.nih.gov/pubmed/29356698
http://dx.doi.org/10.1097/CCO.0000000000000426

Ejemplares similares